Jeff Jones
Stock Analyst at Oppenheimer
(4.00)
# 584
Out of 5,113 analysts
99
Total ratings
32.58%
Success rate
21.69%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Outperform | $57 → $60 | $24.52 | +144.70% | 3 | Jan 26, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $15 → $32 | $23.01 | +39.07% | 6 | Jan 21, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Perform | n/a | $13.97 | - | 12 | Jan 8, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $71.06 | +68.87% | 7 | Dec 9, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $1.76 | +1,320.45% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $9.34 | +467.45% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $23.60 | +86.44% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $26.31 | -4.98% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $6.38 | +166.46% | 4 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $35.08 | +145.15% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $3.71 | +385.18% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.54 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $2.59 | +517.76% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.29 | +3,388.37% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $15.63 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.19 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.87 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.17 | +1,182.05% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $4.55 | +41,108.79% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $3.90 | +28,105.13% | 2 | Nov 17, 2022 |
Pelthos Therapeutics
Jan 26, 2026
Maintains: Outperform
Price Target: $57 → $60
Current: $24.52
Upside: +144.70%
Corvus Pharmaceuticals
Jan 21, 2026
Maintains: Outperform
Price Target: $15 → $32
Current: $23.01
Upside: +39.07%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Perform
Price Target: n/a
Current: $13.97
Upside: -
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $71.06
Upside: +68.87%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $1.76
Upside: +1,320.45%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $9.34
Upside: +467.45%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $23.60
Upside: +86.44%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $26.31
Upside: -4.98%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $6.38
Upside: +166.46%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $35.08
Upside: +145.15%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $3.71
Upside: +385.18%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.54
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.59
Upside: +517.76%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.29
Upside: +3,388.37%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $15.63
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.19
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $2.87
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.17
Upside: +1,182.05%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $4.55
Upside: +41,108.79%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $3.90
Upside: +28,105.13%